Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850062549496627200 |
|---|---|
| author | Shuta Ohara Kenichi Suda Akira Hamada Masato Chiba Masaoki Ito Masaki Shimoji Toshiki Takemoto Junichi Soh Yasuhiro Tsutani |
| author_facet | Shuta Ohara Kenichi Suda Akira Hamada Masato Chiba Masaoki Ito Masaki Shimoji Toshiki Takemoto Junichi Soh Yasuhiro Tsutani |
| author_sort | Shuta Ohara |
| collection | DOAJ |
| description | Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD‐L1 expression. Methods We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD‐L1 expression data. Chi‐squared tests and logistic regression analyses were used to identify clinical factors associated with high PD‐L1 status. Results Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F‐fluorodeoxyglucose positron emission computed tomography (18F‐FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD‐L1 expression. A predictive score for high PD‐L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD‐L1 expression, whereas this proportion increased to 53% for patients with a score of 3. Conclusion These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD‐L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment. |
| format | Article |
| id | doaj-art-01fa212b64f949ff8f69a1fbe25e8ccd |
| institution | DOAJ |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-01fa212b64f949ff8f69a1fbe25e8ccd2025-08-20T02:49:53ZengWileyThoracic Cancer1759-77061759-77142024-11-0115312229223410.1111/1759-7714.15453Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancerShuta Ohara0Kenichi Suda1Akira Hamada2Masato Chiba3Masaoki Ito4Masaki Shimoji5Toshiki Takemoto6Junichi Soh7Yasuhiro Tsutani8Division of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanDivision of Thoracic Surgery, Department of Surgery Kindai University Faculty of Medicine Osaka‐Sayama JapanAbstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD‐L1 expression. Methods We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD‐L1 expression data. Chi‐squared tests and logistic regression analyses were used to identify clinical factors associated with high PD‐L1 status. Results Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F‐fluorodeoxyglucose positron emission computed tomography (18F‐FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD‐L1 expression. A predictive score for high PD‐L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD‐L1 expression, whereas this proportion increased to 53% for patients with a score of 3. Conclusion These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD‐L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment.https://doi.org/10.1111/1759-7714.15453non‐small cell lung cancerplasma fibrinogenprogrammed cell death ligand 1SUVmax |
| spellingShingle | Shuta Ohara Kenichi Suda Akira Hamada Masato Chiba Masaoki Ito Masaki Shimoji Toshiki Takemoto Junichi Soh Yasuhiro Tsutani Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer Thoracic Cancer non‐small cell lung cancer plasma fibrinogen programmed cell death ligand 1 SUVmax |
| title | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
| title_full | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
| title_fullStr | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
| title_full_unstemmed | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
| title_short | Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer |
| title_sort | clinical factors associated with high pd l1 expression in patients with early stage non small cell lung cancer |
| topic | non‐small cell lung cancer plasma fibrinogen programmed cell death ligand 1 SUVmax |
| url | https://doi.org/10.1111/1759-7714.15453 |
| work_keys_str_mv | AT shutaohara clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT kenichisuda clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT akirahamada clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT masatochiba clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT masaokiito clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT masakishimoji clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT toshikitakemoto clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT junichisoh clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer AT yasuhirotsutani clinicalfactorsassociatedwithhighpdl1expressioninpatientswithearlystagenonsmallcelllungcancer |